19 Nov 2018 11:03
Directors' / PDMR Dealing and Grant of Options
19 November 2018
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical company developing a portfolio of innovative products for sexual health and pain relief, today announces that on 19 November 2018 it made its annual grant of options over a total of 1,340,000 ordinary shares of 0.2p each in the Company ("Ordinary Shares") to employees and Directors, of which 650,000 options were granted to Directors and PDMRs as detailed below.
Director | Numberof optionsgranted | Exerciseprice | Exercise period | Total numberof optionsheld followingnotification | Total numberof OrdinaryShares held |
|
|
|
|
|
|
J H Barder | 250,000 | 7.5p | 1 Oct 2020 - 30 Sep 2025 | 1,500,000 | 1,835,972 |
|
|
|
|
|
|
A Hildreth | 200,000 | 7.5p | 1 Oct 2020 - 30 Sep 2025 | 200,000 | 142,857 |
|
|
|
|
|
|
K W James | 200,000 | 7.5p | 1 Oct 2020 - 30 Sep 2025 | 600,000 | 299,581 |
The 1,340,000 options granted were granted under the Futura Medical plc Enterprise Management Incentive Scheme.
The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise. Further disclosures are contained in the tables below.
For further information please contact:
Futura Medical plc James Barder, Chief ExecutiveAngela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.comTel: +44 (0) 1483 685 670
Nominated Adviser and Broker:N+1 SingerAubrey Powell/ Ben Farrow (Corporate Finance)
Tom Salvesen/ Mia Gardner (Corporate Broking)Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimised for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. www.futuramedical.com
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | James Barder | ||||
2 | Reason for the notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Futura Medical plc | ||||
b) | LEI | 21380053QLT46UNV2303 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
b) | Nature of the transaction | Issue of options over Ordinary Shares
| ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
e) | Date of the transaction | 19 November 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Angela Hildreth | ||||
2 | Reason for the notification | |||||
a) | Position/status | Finance Director andChief Operating Officer | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Futura Medical plc | ||||
b) | LEI | 21380053QLT46UNV2303 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
b) | Nature of the transaction | Issue of options over Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
e) | Date of the transaction | 19 November 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Ken James | ||||
2 | Reason for the notification | |||||
a) | Position/status | Executive Directorand Head of R&D | ||||
b) | Initial notification/Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Futura Medical plc | ||||
b) | LEI | 21380053QLT46UNV2303 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary Shares of 0.2 pence each
GB0033278473 | ||||
b) | Nature of the transaction | Issue of options over Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information - Aggregated volume - Price | N/A single transaction | ||||
e) | Date of the transaction | 19 November 2018 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
ENDS
Futura Medical (FUM)